Decentralized Clinical Trials: <em>A Complete Guide</em>
What Are Decentralized Clinical Trials?
Decentralized clinical trials (DCTs) are a modern, patient-centric approach to clinical research that leverages remote technology to conduct studies without requiring participants to travel to a clinical site. Instead of in-person visits, participants complete study activities from home — submitting data through apps, wearable devices, telehealth check-ins, and at-home sample collection kits.
DCTs aren't just for pharmaceutical companies anymore. Consumer brands across supplements, skincare, pet health, biotech, and medical devices are using decentralized trials to generate clinical evidence faster, cheaper, and with more diverse participant populations than traditional site-based studies would allow.
The shift toward decentralized models was accelerated by the COVID-19 pandemic, which forced the industry to adopt remote monitoring and telehealth at scale. But the advantages were so clear that DCTs have become the preferred model for many types of clinical research even post-pandemic.
$9.2BProjected DCT market size by 2024
7.6%Expected annual growth (2024–2034)
3–5×Faster recruitment vs. traditional
Centralized vs. Decentralized Clinical Trials
The fundamental difference comes down to where the study happens. In a centralized (traditional) trial, participants must visit specific clinical sites — hospitals, research centers, or doctor's offices — for every study interaction. In a decentralized trial, some or all of those interactions happen remotely.
Centralized (Traditional)Decentralized (DCT)
Participant locationMust travel to clinical siteParticipates from home
Data collectionIn-person at scheduled visitsContinuous via apps & wearables
Recruitment speedMonths (geographic limitations)Weeks (250K+ database)
Participant diversityLimited to site catchment areaNationwide / global reach
Retention rateLower (travel burden)Higher (convenience)
CostHigh (site fees, staff, travel)70–85% less
CommunicationScheduled site visitsReal-time app + Slack
MonitoringOn-site, periodicContinuous, real-time
It's worth noting that many studies use a hybrid model — combining decentralized elements (remote ePROs, wearable data, telehealth) with targeted in-person visits for activities that require a clinical setting (bloodwork, imaging, device fitting). This gives you the speed and convenience of DCTs with the rigor of site-based assessments when needed.
The Benefits of Decentralized Clinical Trials
Enhanced engagement
Participants join from home, removing travel barriers. This is especially valuable for those with mobility issues, chronic conditions, or in remote areas.
Broader access
When geography isn't a limitation, DCTs can include a more diverse population — leading to more representative, generalizable results.
Better data quality
Wearables and apps collect data continuously and in real-time, reducing recall bias and enabling earlier detection of adverse events.
Cost & time efficiency
No site management fees, no participant travel reimbursement, faster enrollment. Studies that would take 12–24 months finish in 8–16 weeks.
Challenges with Decentralized Clinical Trials
DCTs aren't without challenges. Understanding these upfront helps you design studies that avoid the common pitfalls:
Regulatory Complexity
DCTs often involve participants across multiple jurisdictions, each with different regulations around data privacy (GDPR in Europe, HIPAA in the US). The lack of fully standardized DCT-specific guidelines means study designs require careful regulatory planning. Working with an experienced CRO that understands both FDA guidance and international requirements is essential.
Technology Integration
DCTs rely on multiple digital tools — electronic data capture systems, telehealth platforms, wearable devices, ePRO apps. Integrating these seamlessly to avoid data silos requires a unified platform approach. Fragmented tech stacks are the #1 operational risk in poorly run DCTs.
Participant Access & Digital Literacy
Not all participants have access to the necessary technology (smartphones, reliable internet) or comfort with digital tools. This can affect recruitment diversity and protocol adherence. Good DCT platforms are designed to minimize the digital burden — simple interfaces, SMS fallbacks, and phone-based support.
Quality Control Without On-Site Monitoring
Ensuring protocol adherence without traditional on-site monitoring requires robust remote monitoring systems. Real-time dashboards, automated compliance alerts, and digital audit trails replace the physical clipboard — but the systems need to be designed intentionally.
Citruslabs approach
Citruslabs has been running decentralized trials since 2020 — before the pandemic made them mainstream. Our platform was built decentralized-first, not retrofitted from a site-based model. This means unified data capture, integrated wearable/device support, real-time dashboards, and a 250K+ participant database purpose-built for remote recruitment.
Platforms & Tools for DCTs
Choosing the right platform is critical. The best DCT platforms combine flexibility, scalability, and regulatory compliance in a single system. Key components include:
Telehealth apps: Enable participants to consult with study clinicians virtually, providing continuous care without in-person visits.
Wearable devices: Fitbit, Oura, Whoop, and CGMs track health metrics like heart rate, sleep, activity, glucose, and HRV continuously.
ePRO systems: Electronic patient-reported outcomes collected via smartphone apps. Validated questionnaires delivered on schedule, with automated reminders.
At-home collection kits: Blood, saliva, urine, and stool sample kits shipped to participants with prepaid return labels.
Third-party CROs: Full-service platforms like Citruslabs that centralize study design, recruitment, data management, and stakeholder communication in one system.
Regulatory Landscape & FDA Guidance
The FDA has been actively supportive of decentralized clinical trials. Their official guidance outlines principles for ensuring patient safety and data integrity in remote research settings, emphasizing:
Continuous communication with participants throughout the study
Validation and security of all digital tools used for data collection
Protection of participant privacy and informed consent in remote settings
Equivalent rigor in data quality compared to traditional site-based trials
For consumer health brands (supplements, skincare, wellness products), DCTs typically operate under IRB oversight rather than full FDA regulatory pathways. This means less regulatory complexity than pharmaceutical trials while still maintaining the scientific rigor needed for substantiated claims, publication, and FTC compliance.
For medical devices pursuing 510(k) or De Novo pathways, DCTs can generate the clinical evidence required for regulatory submission — but study designs must be aligned with the specific submission requirements.
Regulatory resources
For more information, refer to the FDA's official DCT guidance and the FTC's advertising and marketing guidelines for substantiation of product claims.
The Growth of the DCT Market
The decentralized clinical trials market has expanded rapidly and shows no signs of slowing. Analysts project the global market will reach $9.2 billion by 2024, with a compound annual growth rate of 7.6% through 2034. Several factors are driving this growth:
Rising demand for real-world evidence (RWE) — increasingly essential across both pharmaceutical and consumer health research
Adoption of digital health technologies — wearables, telehealth, and mobile apps have reached mainstream consumer adoption
Patient-centric trial designs — sponsors recognize that reducing participant burden improves retention, data quality, and study timelines
Post-pandemic momentum — COVID-19 proved that remote trials work, permanently shifting industry expectations
Consumer brand adoption — a growing share of DCT volume now comes from supplements, skincare, pet health, and wellness brands
North America currently leads the market thanks to advanced infrastructure and supportive regulatory frameworks, but Europe and Asia are quickly catching up.
Tips for Running a Successful DCT
Based on our experience running hundreds of decentralized studies, here's what separates successful DCTs from problematic ones:
1. Choose a unified platform
The biggest operational risk in DCTs is a fragmented tech stack. Select a platform that centralizes data storage, participant communication, and stakeholder reporting in one system.
2. Invest in recruitment infrastructure
Fast, targeted recruitment is the single biggest advantage of DCTs — but only if you have access to the right participant pool. A CRO with a large, pre-screened database can enroll studies in weeks rather than months.
3. Prioritize participant experience
The simpler you make the participant experience, the higher your retention rate. This means clear onboarding, minimal app friction, responsive support, and regular check-ins. High retention = better data = stronger claims.
4. Design for your endpoints, not for the model
Don't force a fully decentralized model if your endpoints require in-person assessments. Hybrid designs — combining remote data collection with targeted site visits — often produce the best results.
5. Build in real-time monitoring
Don't wait until the study is over to discover protocol deviations or compliance issues. Real-time dashboards and automated alerts let you catch and correct problems while the study is still running.
Why DCTs Matter for Health & Wellness Brands
For consumer health brands specifically, decentralized clinical trials have fundamentally changed the economics of clinical evidence. Here's what the shift means in practice:
Affordable for DTC brands: Studies that previously cost $300K–$500K+ through traditional CROs now cost a fraction of that amount.
Faster time-to-claim: From study kickoff to substantiated marketing claims in 8–16 weeks, not 12–24 months.
Better data quality: Continuous data from wearables and apps produces richer datasets than periodic in-office visits.
More diverse participants: Nationwide recruitment means your study population better represents your actual customer base.
FTC-ready evidence: With the 2022 FTC guidelines requiring credible scientific evidence for product claims, DCTs provide the fastest path to compliant marketing.
Ready to run a decentralized study?
Citruslabs offers a comprehensive DCT platform built specifically for consumer health brands. From study design and IRB approval through recruitment, data collection, and analysis — all managed on a single platform. Learn how it works →
Frequently Asked Questions
What is the FDA's stance on decentralized clinical trials?
The FDA supports DCTs and has issued formal guidance to ensure they're conducted safely and effectively. Their guidelines emphasize patient safety, data integrity, and the secure use of digital tools. For consumer health products, studies typically operate under IRB oversight rather than direct FDA regulatory pathways.
What is decentralized clinical trial software?
DCT software includes the digital tools used for remote data collection, participant monitoring, and study management. This can include ePRO platforms, telehealth integrations, wearable device data pipelines, and unified study dashboards. The best platforms combine all of these into a single system.
What does remote monitoring mean in DCTs?
Remote monitoring uses digital devices — wearables, apps, and connected health tools — to collect participant data outside of traditional clinical settings. This enables continuous, real-time health data collection rather than the snapshot approach of periodic in-office visits.
How do DCTs compare to traditional trials in terms of data quality?
When properly designed, DCTs often produce higher-quality data than traditional trials. Continuous data collection from wearables and apps reduces recall bias and provides richer datasets. The main risk to data quality in DCTs is a poorly integrated tech stack.
Are DCTs suitable for all types of clinical studies?
DCTs work best for studies where most endpoints can be measured remotely — consumer perception studies, wearable-based biomarkers, ePROs, at-home sample collection. Studies requiring intensive in-person assessments are better suited to hybrid or site-based models. Most consumer health brand studies are excellent candidates for fully decentralized designs.